

# Prognostic significance of tumor-infiltrating T-lymphocyte lesions of advanced stage ovarian cancer

Cancer Immunology, Immunotherapy

58, 449-459

DOI: [10.1007/s00262-008-0583-5](https://doi.org/10.1007/s00262-008-0583-5)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Tumor-host interactions: the role of inflammation. <i>Histochemistry and Cell Biology</i> , 2008, 130, 1079-1090.	0.8	96
3	The Role of Regulatory T Cells in Cancer. <i>Immune Network</i> , 2009, 9, 209.	1.6	92
4	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. <i>PLoS ONE</i> , 2009, 4, e6412.	1.1	354
5	Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. <i>British Journal of Cancer</i> , 2009, 101, 1513-1521.	2.9	89
6	Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e5-e6.	0.8	36
7	Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease. <i>Immunotherapy</i> , 2009, 1, 163-165.	1.0	4
8	Time to Shift the Focus of the War: It Is Not All About the Enemy. <i>Journal of Clinical Oncology</i> , 2009, 27, 168-169.	0.8	5
9	Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 113, 256-263.	0.6	21
10	Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. <i>International Journal of Cancer</i> , 2009, 125, 2104-2113.	2.3	123
11	Microparticle encoding technologies for high-throughput multiplexed suspension assays. <i>Integrative Biology (United Kingdom)</i> , 2009, 1, 345.	0.6	128
12	T Cell Density and Location Can Influence the Prognosis of Ovarian Cancer. <i>Pathology and Oncology Research</i> , 2010, 16, 361-370.	0.9	12
13	Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype. <i>Gynecologic Oncology</i> , 2010, 116, 556-562.	0.6	71
14	Ovarian cancer creates a suppressive microenvironment to escape immune elimination. <i>Gynecologic Oncology</i> , 2010, 117, 366-372.	0.6	134
15	Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 ( $\hat{I} \pm E / \hat{I}^2$ ) Tj ETQq1 1 0.784314 rgBT /Over	0.6	59
16	Immune infiltration in human tumors: a prognostic factor that should not be ignored. <i>Oncogene</i> , 2010, 29, 1093-1102.	2.6	942
17	Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. <i>British Journal of Cancer</i> , 2010, 103, 685-692.	2.9	43
18	Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies. <i>Cancers</i> , 2010, 2, 913-954.	1.7	25
19	Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen. <i>Clinical Cancer Research</i> , 2010, 16, 3594-3606.	3.2	139

#	ARTICLE	IF	CITATIONS
20	Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development. <i>Cancer Research</i> , 2010, 70, 4829-4839.	0.4	61
21	Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 61-95.	0.7	32
22	Tumor Infiltrating Regulatory T Cells: Tractable Targets for Immunotherapy. <i>International Reviews of Immunology</i> , 2010, 29, 461-484.	1.5	5
23	Regulatory T Cells in Cancer. <i>Advances in Cancer Research</i> , 2010, 107, 57-117.	1.9	320
24	Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. <i>Molecular Cancer</i> , 2010, 9, 4.	7.9	123
25	Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2010, 24, 1118-1123.	0.6	86
27	Immunotherapy for Glioblastoma. , 2010, , 365-397.		0
28	Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. <i>Journal of Materials Chemistry</i> , 2010, 20, 547-554.	6.7	85
29	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. <i>British Journal of Cancer</i> , 2011, 105, 93-103.	2.9	1,045
30	HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 <sup>+</sup> T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 10656-10661.	3.3	175
31	Cancer Cell Culture. <i>Methods in Molecular Biology</i> , 2011, , .	0.4	37
32	Isolation of Inflammatory Cells from Human Tumours. <i>Methods in Molecular Biology</i> , 2011, 731, 201-208.	0.4	0
33	Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2011, 23, 13-18.	0.9	35
34	Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. <i>Journal of Immunotherapy</i> , 2011, 34, 516-523.	1.2	25
35	Immunofluorescence-Detected Infiltration of CD4 <sup>+</sup> FOXP3 <sup>+</sup> Regulatory T Cells is Relevant to the Prognosis of Patients With Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1628-1634.	1.2	66
36	Decidual infiltration of FoxP3+ regulatory T <sup>+</sup> cells, CD3+ T <sup>+</sup> cells, CD56+ decidual natural killer cells and Ki-67 trophoblast cells in hydatidiform mole compared to normal and ectopic pregnancies. <i>Molecular Medicine Reports</i> , 2011, 5, 275-81.	1.1	8
37	In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype. <i>Histopathology</i> , 2011, 59, 965-974.	1.6	19
38	A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. <i>Cellular and Molecular Immunology</i> , 2011, 8, 59-66.	4.8	204

#	ARTICLE	IF	CITATIONS
39	Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact. <i>Seminars in Cancer Biology</i> , 2011, 21, 131-138.	4.3	64
40	Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients. <i>Oral Oncology</i> , 2011, 47, 566-570.	0.8	51
41	The neuronal influence on tumor progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 105-118.	3.3	108
42	Association of Intra-tumoral Infiltrating Macrophages and Regulatory T Cells Is an Independent Prognostic Factor in Gastric Cancer after Radical Resection. <i>Annals of Surgical Oncology</i> , 2011, 18, 2585-2593.	0.7	89
43	Vaccine-based clinical trials in ovarian cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 775-784.	2.0	13
44	Tumor immune surveillance and ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 141-151.	2.7	47
45	Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1775-1787.	2.0	56
46	Contribution of the immune system to the chemotherapeutic response. <i>Seminars in Immunopathology</i> , 2011, 33, 353-367.	2.8	30
47	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. <i>Seminars in Immunopathology</i> , 2011, 33, 335-340.	2.8	97
48	Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist. <i>Diagnostic Histopathology</i> , 2011, 17, 80-90.	0.2	9
49	An immunologic portrait of cancer. <i>Journal of Translational Medicine</i> , 2011, 9, 146.	1.8	83
50	Immunity and immune suppression in human ovarian cancer. <i>Immunotherapy</i> , 2011, 3, 539-556.	1.0	102
51	Peritoneal Immune System in Patients with Advance Epithelial Ovarian Cancer. <i>International Reviews of Immunology</i> , 2011, 30, 87-101.	1.5	12
52	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	2.9	151
53	The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature. <i>Clinical Cancer Research</i> , 2012, 18, 3022-3029.	3.2	390
54	Infiltrating CTLs are bothered by HLA-E on tumors. <i>Oncolmmunology</i> , 2012, 1, 92-93.	2.1	14
55	B7-H1 limits the entry of effector CD8 <sup>+</sup> T cells to the memory pool by upregulating Bim. <i>Oncolmmunology</i> , 2012, 1, 1061-1073.	2.1	38
56	Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen. <i>Current Pharmaceutical Design</i> , 2012, 18, 3804-3811.	0.9	12

#	ARTICLE	IF	CITATIONS
57	Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1243-1253.	2.0	34
58	Inflammation and ovarian cancer. <i>Cytokine</i> , 2012, 58, 133-147.	1.4	251
59	Distribution of Th17 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer. <i>Clinica Chimica Acta</i> , 2012, 413, 1848-1854.	0.5	36
60	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1323-1343.	2.1	203
61	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873
62	Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses. <i>PLoS ONE</i> , 2012, 7, e47190.	1.1	25
63	Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 274.	1.0	54
64	The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma. <i>Neoplasma</i> , 2012, 59, 475-485.	0.7	11
65	Multiplexed Immunoassays. , 2012, , .		2
66	Combining immunotherapy and targeted therapies in cancer treatment. <i>Nature Reviews Cancer</i> , 2012, 12, 237-251.	12.8	1,261
67	Potential of a p53 $\alpha$ 6SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study. <i>International Journal of Cancer</i> , 2012, 131, E670-80.	2.3	81
68	T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. <i>Cancer Research</i> , 2012, 72, 2162-2171.	0.4	663
69	Weapons Ovarian Epithelial Tumors May Use in Immune Escape: An Immunohistochemical Correlational Study. <i>Pathology and Oncology Research</i> , 2012, 18, 509-518.	0.9	5
70	Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2012, 124, 192-198.	0.6	527
71	Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. <i>Gynecologic Oncology</i> , 2012, 125, 186-193.	0.6	25
72	Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. <i>BMC Clinical Pathology</i> , 2012, 12, 5.	1.8	32
73	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012, 10, 33.	1.8	93
74	Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 397-407.	2.0	12

#	ARTICLE	IF	CITATIONS
75	Immunological monitoring of the tumor immunoenvironment for clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 239-247.	2.0	24
76	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 147.	1.8	56
77	FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 39.	3.5	36
78	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
79	Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study. <i>BMC Cancer</i> , 2013, 13, 162.	1.1	48
80	The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 761-772.	2.0	22
81	Identity crisis of Th17 cells: Many forms, many functions, many questions. <i>Seminars in Immunology</i> , 2013, 25, 263-272.	2.7	68
82	Digital Genomic Quantification of Tumor-Infiltrating Lymphocytes. <i>Science Translational Medicine</i> , 2013, 5, 214ra169.	5.8	58
83	Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013, 13, 422.	1.1	59
84	FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 381-390.	1.1	55
85	<i>Cancer Immunoediting</i> , 2013, , 85-99.		7
86	Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance. <i>Cancer Microenvironment</i> , 2013, 6, 147-157.	3.1	111
87	Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. <i>International Journal of Pharmaceutics</i> , 2013, 445, 171-180.	2.6	69
88	<i>The Tumor Immunoenvironment</i> , 2013, , .		4
89	Characterization of the inflammatory response to solid cancer metastases in the human brain. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 69-81.	1.7	81
90	Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation. <i>Molecular Therapy</i> , 2013, 21, 338-347.	3.7	63
91	Determination of Tumor-infiltrating CD8+ Lymphocytes in Human Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 269-276.	0.9	9
92	Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 1170-1179.	0.6	80

#	ARTICLE	IF	CITATIONS
93	CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg. <i>Cancer Immunology Research</i> , 2013, 1, 303-308.	1.6	21
94	Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. <i>Frontiers in Oncology</i> , 2013, 3, 256.	1.3	358
95	Heterozygous Genetic Variations of <i>FOXP3</i> in Xp11.23 Elevate Breast Cancer Risk in Chinese Population via Skewed X-Chromosome Inactivation. <i>Human Mutation</i> , 2013, 34, n/a-n/a.	1.1	26
96	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. <i>Clinical Cancer Research</i> , 2013, 19, 4079-4091.	3.2	301
97	IRF-1 responsiveness to IFN- $\beta$ predicts different cancer immune phenotypes. <i>British Journal of Cancer</i> , 2013, 109, 76-82.	2.9	58
98	The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. <i>Neuro-Oncology</i> , 2013, 15, 1479-1490.	0.6	72
99	Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor. <i>Molecular and Clinical Oncology</i> , 2013, 1, 633-638.	0.4	4
100	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 55.	0.8	17
101	Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e54029.	1.1	56
102	Immune Cells in the Normal Ovary and Spontaneous Ovarian Tumors in the Laying Hen ( <i>Gallus</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.1	11
103	Deconvolution of the Gene Expression Profiles of Valuable Banked Blood Specimens for Studying the Prognostic Values of Altered Peripheral Immune Cell Proportions in Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e100934.	1.1	7
104	Gut Microbiota and the Paradox of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 157.	2.2	29
105	Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. <i>British Journal of Cancer</i> , 2014, 110, 1535-1544.	2.9	30
106	Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low-versus High-Volume Ascites. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	27
107	FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment. <i>Thyroid</i> , 2014, 24, 339-346.	2.4	23
108	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 103-114.	1.4	6
109	Epithelial ovarian cancer - more data, more questions?. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 479-486.	0.5	13
110	Circulating T-regulatory cells in PNET: A prospective study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 228-232.	0.8	6

#	ARTICLE	IF	CITATIONS
111	The Immune Microenvironment: A Major Player in Human Cancers. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 13-26.	0.9	63
112	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. <i>Oncolmmunology</i> , 2014, 3, e962397.	2.1	27
113	Urokinase-Type Plasminogen Activator Deficiency Promotes Neoplasmatogenesis in the Colon of Mice. <i>Translational Oncology</i> , 2014, 7, 174-187.e5.	1.7	20
114	The immune network in pancreatic cancer development and progression. <i>Oncogene</i> , 2014, 33, 2956-2967.	2.6	181
115	Increased frequency of CD4+ CD25+ FOXP3+ cells correlates with the progression of 4-nitroquinoline1-oxide-induced rat tongue carcinogenesis. <i>Clinical Oral Investigations</i> , 2014, 18, 1725-1730.	1.4	18
116	Prognostic biomarkers in endometrial and ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 315-331.	1.4	43
117	A Review of the Application of Inflammatory Biomarkers in Epidemiologic Cancer Research. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1729-1751.	1.1	123
119	Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 389-398.	1.2	15
120	Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. <i>Blood</i> , 2015, 126, 2882-2891.	0.6	81
121	Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2015, 5, 15179.	1.6	706
122	CD45RO+ Memory T Lymphocytes "a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. <i>Neoplasia</i> , 2015, 17, 839-848.	2.3	62
123	A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 102.	1.8	221
124	Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. <i>Wspolczesna Onkologia</i> , 2015, 4, 290-299.	0.7	21
125	Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival. <i>BioMed Research International</i> , 2015, 1-9.	0.9	20
126	IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. <i>Oncolmmunology</i> , 2015, 4, e994446.	2.1	336
127	PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 926-935.	1.6	169
128	Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. <i>Head and Neck</i> , 2015, 37, 449-459.	0.9	51
129	Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. <i>Tumor Biology</i> , 2015, 36, 4811-4817.	0.8	43



#	ARTICLE	IF	CITATIONS
130	Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. <i>European Journal of Immunology</i> , 2015, 45, 922-931.	1.6	74
131	Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer. <i>Tumor Biology</i> , 2015, 36, 5407-5414.	0.8	12
132	Low Infiltration of Peritumoral Regulatory T Cells Predicts Worse Outcome Following Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 180-186.	0.7	36
134	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. <i>British Journal of Cancer</i> , 2015, 113, 786-793.	2.9	20
135	The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 <sup>-/-</sup> murine model of ovarian cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 551-556.	1.0	133
136	Tumor infiltrating lymphocytes in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 807-820.	1.5	257
137	Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 337-347.	2.0	67
138	Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. <i>Cancer Gene Therapy</i> , 2015, 22, 198-206.	2.2	25
139	CD20 <sup>+</sup> T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. <i>Onc Immunology</i> , 2015, 4, e999536.	2.1	17
140	AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer. <i>European Journal of Pharmacology</i> , 2015, 766, 63-75.	1.7	19
141	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. <i>Current Cancer Therapy Reviews</i> , 2016, 12, 23-36.	0.2	0
142	The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. <i>Oncotarget</i> , 2016, 7, 7940-7951.	0.8	54
143	Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. <i>Journal of Immunology Research</i> , 2016, 2016, 1-25.	0.9	49
144	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. <i>Vaccines</i> , 2016, 4, 28.	2.1	372
145	Involvement of Regulatory T Cells and Their Cytokines Repertoire in Chemopreventive Action of Fish Oil in Experimental Colon Cancer. <i>Nutrition and Cancer</i> , 2016, 68, 1181-1191.	0.9	11
146	Software tools for simultaneous data visualization and T cell epitopes and disorder prediction in proteins. <i>Journal of Biomedical Informatics</i> , 2016, 60, 120-131.	2.5	11
147	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.	6.9	271
148	VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. <i>Clinical Cancer Research</i> , 2016, 22, 4249-4258.	3.2	28

#	ARTICLE	IF	CITATIONS
149	Therapeutic targets and new directions for antibodies developed for ovarian cancer. <i>MAbs</i> , 2016, 8, 1437-1455.	2.6	15
150	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
151	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3025-3036.	3.2	124
153	CD19+IL-10+ regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4+ T cells to CD4+Foxp3+ regulatory T cells. <i>Oral Oncology</i> , 2016, 53, 27-35.	0.8	130
154	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. <i>Seminars in Immunology</i> , 2016, 28, 73-80.	2.7	56
155	Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. <i>Oncolimmunology</i> , 2016, 5, e1122863.	2.1	2
156	The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNF $\alpha$ /IL17 Dependent. <i>Clinical Cancer Research</i> , 2016, 22, 2207-2216.	3.2	22
157	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. <i>Drug Resistance Updates</i> , 2016, 24, 55-69.	6.5	52
158	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 714-724.	3.2	51
159	Immunoprofiling as a predictor of patient's response to cancer therapy" promises and challenges. <i>Current Opinion in Immunology</i> , 2017, 45, 60-72.	2.4	39
160	Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. <i>Gynecologic Oncology</i> , 2017, 145, 413-419.	0.6	19
161	Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 15-25.	3.2	33
162	Epigenetics and immunotherapy: The current state of play. <i>Molecular Immunology</i> , 2017, 87, 227-239.	1.0	167
163	Differential distribution of tumor-associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors. <i>Oncology Letters</i> , 2017, 13, 159-166.	0.8	18
164	Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force. <i>Journal of Leukocyte Biology</i> , 2017, 102, 407-421.	1.5	32
165	Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients. <i>Oncology Letters</i> , 2017, 14, 3379-3386.	0.8	3
166	Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors. <i>Scientific Reports</i> , 2017, 7, 10376.	1.6	56
167	Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. <i>Melanoma Research</i> , 2017, 27, 32-42.	0.6	16

#	ARTICLE	IF	CITATIONS
168	Cancer Immunity and Immune Evasion Mechanisms. , 2017, , 195-220.		1
169	Antigen processing and immune regulation in the response to tumours. Immunology, 2017, 150, 16-24.	2.0	133
170	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer, 2017, 20, 602-611.	2.7	76
171	Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Human Pathology, 2017, 59, 55-61.	1.1	58
172	The Different Functional Distribution of “Not Effector” T Cells (Treg/Tnull) in Colorectal Cancer. Frontiers in Immunology, 2017, 8, 1900.	2.2	39
173	The Prognostic Value of Baseline Lymphocyte, Neutrophil, and Monocyte Counts in Locally Advanced Cervical Carcinoma Treated with Radiation. Obstetrics and Gynecology International, 2017, 2017, 1-9.	0.5	3
174	Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. Mediators of Inflammation, 2017, 2017, 1-9.	1.4	33
175	<i>FOXP3</i> Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes. Disease Markers, 2017, 2017, 1-8.	0.6	12
176	Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer, 2017, 17, 657.	1.1	48
177	Ascitic Fluid in Ovarian Carcinoma “ From Pathophysiology to the Treatment. , 2017, , .		3
178	The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget, 2017, 8, 15621-15631.	0.8	148
179	Engineering chimeric antigen receptor-T cells for cancer treatment. Molecular Cancer, 2018, 17, 32.	7.9	57
180	Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA“Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Human Gene Therapy, 2018, 29, 614-625.	1.4	56
181	CD103 + CD8 + T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade. Cellular Immunology, 2018, 325, 48-55.	1.4	20
182	“ cells and tumor microenvironment: A helpful or a dangerous liason?. Journal of Leukocyte Biology, 2018, 103, 485-492.	1.5	19
183	Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Human Pathology, 2018, 74, 135-147.	1.1	39
184	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. Oncoimmunology, 2018, 7, e1393133.	2.1	17
185	The metabolic cross“talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role. Medicinal Research Reviews, 2018, 38, 1235-1254.	5.0	69

#	ARTICLE	IF	CITATIONS
186	Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 703-709.	1.8	16
187	High-throughput sequencing of the immune repertoire in oncology: Applications for clinical diagnosis, monitoring, and immunotherapies. <i>Cancer Letters</i> , 2018, 416, 42-56.	3.2	26
188	Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. <i>International Journal of Cancer</i> , 2018, 143, 8-15.	2.3	28
190	Fusobacterium and Colorectal Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 371.	1.3	89
191	Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer. <i>Cancer Investigation</i> , 2018, 36, 395-405.	0.6	28
192	Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled. <i>Cancers</i> , 2018, 10, 295.	1.7	49
193	Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 8111-8119.	0.8	13
194	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. <i>Cancer Biomarkers</i> , 2018, 22, 467-476.	0.8	33
195	Multiomics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome. <i>American Journal of Reproductive Immunology</i> , 2018, 80, e12975.	1.2	18
196	The homeodomain transcription factor MEIS1 triggers chemokine expression and is involved in CD8+ T lymphocyte infiltration in early stage ovarian cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 1251-1263.	1.3	19
197	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 515-524.	0.6	16
198	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	1.7	38
199	Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. <i>Cancers</i> , 2018, 10, 244.	1.7	40
200	The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. <i>Cancers</i> , 2018, 10, 242.	1.7	97
201	Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. <i>Molecular Cancer</i> , 2018, 17, 91.	7.9	60
202	Toward innovative combinational immunotherapy: A systems biology perspective. <i>Cancer Treatment Reviews</i> , 2018, 68, 1-8.	3.4	13
203	High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy. <i>BMC Cancer</i> , 2018, 18, 425.	1.1	24
204	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	2.0	16

#	ARTICLE	IF	CITATIONS
205	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. <i>Cancers</i> , 2019, 11, 1217.	1.7	36
206	The Therapeutic Strategies of Regulatory T Cells in Malignancies and Stem Cell Transplantations. <i>Journal of Oncology</i> , 2019, 2019, 1-6.	0.6	6
207	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC. <i>Cancer Immunology Research</i> , 2019, 7, 1202-1213.	1.6	24
208	Turning the Tide Against Regulatory T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 279.	1.3	47
209	Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 668.	1.7	45
210	DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 3445-3454.	0.4	59
211	TNFR2-expressing CD4+Foxp3+ regulatory T cells in cancer immunology and immunotherapy. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 101-117.	0.9	15
212	Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. <i>International Journal of Cancer</i> , 2019, 145, 1958-1969.	2.3	21
213	The association of <i>FOXP3</i> gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysis. <i>Bioscience Reports</i> , 2019, 39, .	1.1	5
214	Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2537-2548.	1.5	10
215	Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study. <i>Gynecologic Oncology</i> , 2019, 152, 259-264.	0.6	57
216	Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 371-378.	1.1	37
217	Follicular regulatory T cells infiltrated the ovarian carcinoma and resulted in CD8 T cell dysfunction dependent on IL-10 pathway. <i>International Immunopharmacology</i> , 2019, 68, 81-87.	1.7	33
218	Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas. <i>Oncology</i> , 2019, 96, 93-100.	0.9	3
219	The Role of Stroma in Ovarian Cancer. <i>Immunological Investigations</i> , 2020, 49, 406-424.	1.0	9
220	The immune landscape of chondrosarcoma - potential for therapeutic targeting of CSFR1+ macrophages. <i>Journal of Bone Oncology</i> , 2020, 20, 100271.	1.0	23
221	Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2091-2100.	0.9	10
222	FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. <i>Cancer Letters</i> , 2020, 490, 174-185.	3.2	169

#	ARTICLE	IF	CITATIONS
223	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , 2020, 20, 662-680.	12.8	860
224	Clinical outcomes of prexasertib monotherapy in recurrent <i>BRCA</i> wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. , 2020, 8, e000516.		12
225	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	1.6	16
226	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16
227	The investigation of T-cell receptor subtypes in ovarian cancer: effects on survival and prognostic factors. <i>Journal of Obstetrics and Gynaecology</i> , 2021, 41, 951-955.	0.4	1
228	Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma. <i>Disease Markers</i> , 2020, 2020, 1-13.	0.6	10
229	FoxP3 promotes lymph node metastasis in patients with papillary thyroid carcinoma complicated with Hashimoto's thyroiditis. <i>Translational Cancer Research</i> , 2020, 9, 1337-1350.	0.4	2
230	Nanoengineered targeting strategy for cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 902-910.	2.8	23
231	Comparative phenotypes of peripheral blood and spleen cells from cancer patients. <i>International Immunopharmacology</i> , 2020, 85, 106655.	1.7	4
232	An Overview on ERAP Roles in Infectious Diseases. <i>Cells</i> , 2020, 9, 720.	1.8	34
233	OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. <i>British Journal of Cancer</i> , 2020, 122, 1507-1517.	2.9	48
234	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
235	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8
236	Tissue-Infiltrating Lymphocytes as a Predictive Factor for Recurrence in Patients with Curatively Resected Colon Cancer: A Propensity Score Matching Analysis. <i>Oncology</i> , 2020, 98, 680-688.	0.9	4
237	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. <i>Oncimmunology</i> , 2020, 9, 1760705.	2.1	11
238	Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. <i>Gastroenterology</i> , 2020, 158, 1682-1697.e1.	0.6	58
239	Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1803-1810.	2.9	23
240	The Proportion and Prognostic Significance of T-Regulatory Cells in Patients with Gynecological Cancers: A Systematic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2020, 11, 3340-3348.	1.2	5

#	ARTICLE	IF	CITATIONS
241	Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1278, 229-256.	0.8	5
242	Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1935104.	2.1	10
243	Computational study for suppression of CD25/IL-2 interaction. <i>Biological Chemistry</i> , 2021, 402, 167-178.	1.2	0
244	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. <i>Npj Vaccines</i> , 2021, 6, 36.	2.9	27
245	Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 622182.	1.3	12
246	A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 649710.	1.3	16
247	Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3905-3918.	1.3	11
248	Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 133-143.	1.8	14
249	Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms. <i>Gene</i> , 2021, 796-797, 145799.	1.0	9
250	Role of regulatory T cells on a simple tumor-immune interaction system. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2021, 98, 105765.	1.7	1
251	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 33-45.	4.8	47
252	Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. <i>Seminars in Cancer Biology</i> , 2021, 77, 144-166.	4.3	50
253	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. <i>Cancers</i> , 2021, 13, 4553.	1.7	6
254	Prognostic Value of CD45RO <sup>+</sup> T-Cell Expression in Patients With Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 4515-4522.	0.5	3
255	circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation. <i>Cancer Gene Therapy</i> , 2023, 30, 559-566.	2.2	8
256	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021, 100, 102294.	3.4	21
257	Pericytes cross-talks within the tumor microenvironment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188608.	3.3	21
258	The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?. <i>Open Journal of Obstetrics and Gynecology</i> , 2021, 11, 146-161.	0.1	2

#	ARTICLE	IF	CITATIONS
259	MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer. <i>Bioengineered</i> , 2021, 12, 3603-3620.	1.4	12
260	Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 215, 55-61.	0.5	7
261	Neutralization of TGF $\beta$ <sup>2</sup> Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 602-611.	1.9	5
262	Inverse correlation between CD8+inflammatory cells and E-cadherin expression in gallbladder cancer: Tissue microarray and imaging analysis. <i>World Journal of Clinical Cases</i> , 2017, 5, 1.	0.3	7
263	The Accumulation and Prognosis Value of Tumor Infiltrating IL-17 Producing Cells in Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2011, 6, e18219.	1.1	118
264	Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma. <i>PLoS ONE</i> , 2013, 8, e82406.	1.1	22
265	CD4+CD25 <sup>hi</sup> CD127 <sup>low</sup> Regulatory T Cells Are Increased in Oral Squamous Cell Carcinoma Patients. <i>PLoS ONE</i> , 2014, 9, e103975.	1.1	52
266	Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?. <i>Acta Facultatis Medicae Naissensis</i> , 2016, 33, 237-246.	0.1	1
267	Association of FOXP3 Gene Polymorphism with Chronic Hepatitis B in Chinese Population. <i>Infection International</i> , 2012, 1, 191-195.	0.1	1
268	The Immune System in the Pathogenesis of Ovarian Cancer. <i>Critical Reviews in Immunology</i> , 2013, 33, 137-164.	1.0	55
269	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCR $\beta$ <sup>+</sup> CD8 $\alpha$ <sup>+</sup> T cells that can be targeted for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 75130-75144.	0.8	64
270	Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells. <i>Oncotarget</i> , 2016, 7, 7318-7328.	0.8	15
271	Strategic Combination Therapies for Ovarian Cancer. <i>Current Cancer Drug Targets</i> , 2020, 20, 573-585.	0.8	2
272	Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAIL. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2013, 04, .	0.2	6
273	The advanced lung cancer inflammation index predicts short and long-term outcomes in patients with colorectal cancer following surgical resection: a retrospective study. <i>PeerJ</i> , 2020, 8, e10100.	0.9	20
274	The Dog as a Model to Study the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 123-152.	0.8	3
275	Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model. <i>Clinical and Translational Medicine</i> , 2021, 11, e551.	1.7	3
276	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30



#	ARTICLE	IF	CITATIONS
277	The TNF-Î±/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725473.	1.8	21
279	The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. , 2011, , 211-228.		1
280	Impact of Obesity and Aging on the Tumor Immuno-Environment. , 2013, , 223-250.		0
281	Evaluation of the Tumor Immunoenvironment in Clinical Trials. , 2013, , 695-706.		1
283	IMMUNOSUPPRESSIVE POTENTIAL OF PERIPHERAL REGULATORY T-LYMPHOCYTES IN THE PROCESS OF TUMOR PROGRESSION IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMAS. <i>Voprosy Onkologii</i> , 2018, 64, 400-407.	0.1	1
284	Association of absolute lymphocyte count and circulating CD4+ and CD8+ t-cells with positive clinical outcome in survivors of cancer: An observational study. <i>Indian Journal of Medical Specialities</i> , 2019, 10, 149.	0.1	1
285	Association of absolute lymphocyte count and circulating CD4+ and CD8+ t-cells with positive clinical outcome in survivors of cancer: An observational study. <i>Indian Journal of Medical Specialities</i> , 2019, 10, 149.	0.1	0
286	Birinci basamak kemoterapi alan metastatik mesane kanser hastalarÄ±nda saÄŸkalÄ±mÄ± ÄŸngÄŸrmede tedavi ÄŸncesi nÄŸtrofil-lenfosit oranÄ± ve platelet-lenfosit oranÄ±nÄ±n rolÄ¼. <i>OrtadoÄŸu TÄ±p Dergisi</i> , 0, , .	0.1	0
287	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 23-35.	0.6	1
288	Epithelial ovarian cancer: a review of preoperative imaging features indicating suboptimal surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e57.	1.0	3
289	Therapeutic Vaccines for Gastrointestinal Malignancies. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 113-158.	0.2	1
290	The Immune Landscape in Women Cancers. <i>Cancer Treatment and Research</i> , 2020, 180, 215-249.	0.2	3
291	Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model. <i>American Journal of Cancer Research</i> , 2012, 2, 204-13.	1.4	8
292	Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. <i>Cancer Immunity</i> , 2013, 13, 1.	3.2	43
294	Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1803-13.	1.3	13
295	Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. <i>American Journal of Cancer Research</i> , 2015, 5, 3276-85.	1.4	28
296	The diverse roles of the TNF axis in cancer progression and metastasis. <i>Trends in Cancer Research</i> , 2016, 11, 1-27.	1.6	77
297	Immune reaction by cytoreductive prostatectomy. <i>American Journal of Clinical and Experimental Urology</i> , 2019, 7, 64-79.	0.4	2

#	ARTICLE	IF	CITATIONS
298	Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 260.	1.7	26
299	FOXP3 expression in FOXP3+ tumor cells promotes hepatocellular cells metastasis. <i>Translational Cancer Research</i> , 2020, 9, 5868-5881.	0.4	4
300	The Potential Mechanism of Cancer Patients Appearing More Vulnerable to SARS-CoV-2 and Poor Outcomes: A Pan-Cancer Bioinformatics Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 804387.	2.2	8
301	MicroRNAs as potential immunotherapeutic modulators in cancer. , 2022, , 165-183.		0
302	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. <i>Cancers</i> , 2022, 14, 1098.	1.7	8
303	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. <i>Cancers</i> , 2022, 14, 1406.	1.7	13
304	CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC. <i>Cancers</i> , 2022, 14, 1541.	1.7	6
306	Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1006-1016.	1.1	6
307	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	3.2	26
308	On the Prognostic Power of Tumor-Infiltrating Lymphocytes – A Critical Commentary. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
309	Suppressing MDSC Infiltration in Tumor Microenvironment Serves as an Option for Treating Ovarian Cancer Metastasis. <i>International Journal of Biological Sciences</i> , 2022, 18, 3697-3713.	2.6	10
310	Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	0.9	0
311	Development of survival predictors for high-grade serous ovarian cancer based on stable radiomic features from computed tomography images. <i>IScience</i> , 2022, 25, 104628.	1.9	8
313	Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2523-2536.	1.2	3
314	Therapeutic targeting of regulatory T cells in cancer. <i>Trends in Cancer</i> , 2022, 8, 944-961.	3.8	44
315	Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer. <i>Oncolimmunology</i> , 2022, 11, .	2.1	16
316	CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF- $\beta$ 2 signaling. , 2022, 10, e003750.		6
317	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	50

#	ARTICLE	IF	CITATIONS
318	Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews. <i>Cancers</i> , 2022, 14, 3834.	1.7	11
319	Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?. , 2023, , 91-115.		0
320	Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
321	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4344.	1.7	13
322	Immune Tumor Microenvironment in Ovarian Cancer Ascites. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10692.	1.8	15
323	Hallmarks of Cancer Expression in Oral Lichen Planus: A Scoping Review of Systematic Reviews and Meta-Analyses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13099.	1.8	5
324	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. <i>Cancers</i> , 2022, 14, 5332.	1.7	5
325	Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. <i>Radiotherapy and Oncology</i> , 2022, 177, 81-94.	0.3	13
326	Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
328	Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	1
329	An Overview of the Molecular Cues and Their Intracellular Signaling Shared by Cancer and the Nervous System: From Neurotransmitters to Synaptic Proteins, Anatomy of an All-Inclusive Cooperation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14695.	1.8	2
331	Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 603.	1.0	2
332	Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1973.	1.8	5
333	Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses. , 2023, 2, .		3
334	Phase I Study of a Multivalent WT1 Peptide Vaccine (Galipepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. <i>Cancers</i> , 2023, 15, 1458.	1.7	3
335	Implication of <sup>99m</sup> Tc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells. , 2023, 11, e005925.		1
336	Tumor-Infiltrating Lymphocytes (TILs) and Gynecological Cancers. , 2023, , .		1